Phase IB/II study to evaluate safety and preliminary efficacy of the WEE1 inhibitor Debio 0123 in combination with sacituzumab govitecan (SG) in triple-negative or hormone receptor–positive (HR+)/HER2-negative (HER2–) advanced breast cancer (ABC): The WIN-B study.
Year: 2025
Type: article
Source: Journal of Clinical Oncology
Institutions: University of Bristol, MedSIR (Spain), Debiopharm (Switzerland), Hospital Universitario de Torrejón, Universidad Europea de Madrid, Universidad Cardenal Herrera CEU, Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana, Hospital Arnau de Vilanova
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4410823310